great post mo 4kids It currently is very c
Post# of 72440
4kids
It currently is very cheap for an entity to keep IPIX share price down based on the current 11 cent or so share price. Take an example where a manipulator has a $27,500 daily bank-roll to buy up to 250,000 shares. For this example let’s say they are willing to take a half a cent loss on their transactions to keep the stock artificially low. A half cent loss currently represents 5% of the total share price and on 250,000 shares is only $1,250. That $1,250 daily loss is probably less expensive than what they are paying their paid bashers on a daily basis. The only reason they have to take this minor loss is that there are still some pesky longs that keep nibbling away at these depressed values. Both the paid bashers and the daily transaction hits are simply the price of poker to them.
Now let’s use the same example and we wake up some morning soon and the share price has spiked up to $3.00/share after a partnership announcement. There is an abundance of NEW buyers beyond the pesky longs that have been holding on for dear life. These new buyers drive REAL volume up to levels that we have previously never seen on IPIX as the entire biotech, pharmaceutical and Wall Street industries take notice and buy their tickets for a piece of a rising biotech star.
Back to our manipulator. That same $27,500 bank-roll would now only buy 9,166 shares vs the 250,000 shares currently. 9,166 shares will be a rounding error if legit volume raises to 500,000 to 1M shares daily. To control that same 5% of overall share price at $3 as the example above the manipulator would now have to take a daily hit of 15 cents vs a half a cent per share. A 15 cent loss on the same 250,000 shares would now be $37,500 loss per day vs only $1,250 currently. The cost of poker has just significantly gone up for the manipulator. The manipulator knows that $3/share is just the start as many of the new investors are just as pesky as the current longs and are looking for $10-$20/share exit strategies as Brilacidin and Kevetrin advance to market.
At some point the law of supply and demand wins. It always does.